A
86.17
1.90 (2.25%)
| Previous Close | 84.27 |
| Open | 85.00 |
| Volume | 504,936 |
| Avg. Volume (3M) | 476,595 |
| Market Cap | 4,632,128,512 |
| Price / Sales | 29.53 |
| Price / Book | 9.86 |
| 52 Weeks Range |
| Profit Margin | -25.94% |
| Operating Margin (TTM) | -129.14% |
| Diluted EPS (TTM) | -0.710 |
| Quarterly Revenue Growth (YOY) | 74.00% |
| Total Debt/Equity (MRQ) | 13.53% |
| Current Ratio (MRQ) | 4.29 |
| Operating Cash Flow (TTM) | 20.81 M |
| Levered Free Cash Flow (TTM) | 37.50 M |
| Return on Assets (TTM) | -6.29% |
| Return on Equity (TTM) | -10.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arcellx, Inc. | Bullish | Bullish |
AIStockmoo Score
2.4
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 2.38 |
|
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 12.62% |
| % Held by Institutions | 94.93% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 136.00 (Truist Securities, 57.83%) | Buy |
| Median | 115.00 (33.46%) | |
| Low | 100.00 (B of A Securities, 16.05%) | Buy |
| Average | 113.33 (31.52%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 97.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 12 Nov 2024 | 136.00 (57.83%) | Buy | 100.48 |
| HC Wainwright & Co. | 08 Nov 2024 | 115.00 (33.46%) | Buy | 103.06 |
| 06 Nov 2024 | 95.00 (10.25%) | Buy | 92.98 | |
| Needham | 08 Nov 2024 | 105.00 (21.85%) | Buy | 103.06 |
| 06 Nov 2024 | 96.00 (11.41%) | Buy | 92.98 | |
| Piper Sandler | 08 Nov 2024 | 115.00 (33.46%) | Buy | 103.06 |
| B of A Securities | 06 Nov 2024 | 100.00 (16.05%) | Buy | 92.98 |
| Baird | 06 Nov 2024 | 106.00 (23.01%) | Buy | 92.98 |
| Morgan Stanley | 06 Nov 2024 | 106.00 (23.01%) | Buy | 92.98 |
| Stifel | 18 Oct 2024 | 122.00 (41.58%) | Buy | 96.86 |
| Canaccord Genuity | 17 Oct 2024 | 115.00 (33.46%) | Buy | 95.27 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |